Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors

Leukemia
Gaëtan JegoCatherine Pellat-Deceunynck

Abstract

Multiple myeloma (MM) patients are strongly vulnerable to infections, which remain a major cause of death. During infection, human immune cells sense the presence of invading pathogens through the Toll-like receptor family (TLR), which recognizes pathogen-associated molecular patterns (PAMP). We hypothesized that MM cells also could sense the presence of microorganisms, thus promoting myeloma disease progression. Here, we report that human myeloma cell lines (HMCL) and primary myeloma cells express a broad range of TLR, and are sensitive to the corresponding PAMP. Toll-like receptor 1, 7 and 9 are most frequently expressed by HMCL. The expression pattern of TLR does not correlate with the one of B cells, as TLR2 and 10 are lost while TLR3, 4 and 8 are acquired by some HMCL. Culture with TLR7- and TLR9-ligands saves HMCL from serum-deprivation or dexamethasone-induced apoptosis. Similarly, both ligands increase myeloma cell growth. These effects are mediated by an autocrine secretion of interleukin-6 (IL-6) since the neutralization of IL-6 blocks the growth and survival of HMCL. Thus, TLR expression and function are not restricted to the cells of the immune system and could be of advantage for cancer cells. In MM, recurrent infe...Continue Reading

References

Jun 5, 1997·The New England Journal of Medicine·R Bataille, J L Harousseau
Jan 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·G Hartmann, A M Krieg
Dec 29, 2000·Nature·H HemmiS Akira
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·C Pellat-DeceunynckR Bataille
Apr 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Veit HornungGunther Hartmann
Oct 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Karin LoréRichard A Koup
Feb 21, 2004·Science·Sandra S DieboldCaetano Reis e Sousa
Jul 6, 2004·Immunological Reviews·Bali Pulendran
Sep 30, 2004·Nature Immunology·Akiko Iwasaki, Ruslan Medzhitov
Nov 27, 2004·Current Directions in Autoimmunity·Gaetan JegoJacques Banchereau
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Arun T KamathDavid F Tough
Feb 17, 2005·European Journal of Immunology·Maria ManukyanHolger Heine
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernd JahrsdorferGunther Hartmann
Mar 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Isabelle Béatrice Bekeredjian-DingGunther Hartmann
Jun 17, 2005·Cancer Research·Bo HuangHuabao Xiong

❮ Previous
Next ❯

Citations

Jul 22, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Zhao XiaoxiaTai Guixiang
Sep 4, 2012·Archives of Pharmacal Research·Shaherin BasithSangdun Choi
Mar 25, 2009·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Jan ZeromskiMariusz Kaczmarek
Oct 11, 2008·Nature Reviews. Cancer·Bostjan SerugaIan F Tannock
Dec 5, 2008·Nature Reviews. Cancer·Seth Rakoff-Nahoum, Ruslan Medzhitov
Jul 9, 2008·Biochemistry. Biokhimii︠a︡·S Rakoff-Nahoum, R Medzhitov
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·S Vincent Rajkumar
May 4, 2007·The Journal of Clinical Investigation·Wan-Wan Lin, Michael Karin
Mar 20, 2010·The Journal of Clinical Investigation·Julien Cherfils-ViciniIsabelle Cremer
Apr 27, 2012·Journal of Translational Medicine·Yi ZhuBi-Fang Deng
Aug 17, 2011·Journal of Nucleic Acids·Esmerina Tili, Jean-Jacques Michaille
May 19, 2009·Cancer Immunology, Immunotherapy : CII·Evelien L J M SmitsViggo F I Van Tendeloo
Aug 13, 2009·Leukemia & Lymphoma·Marta MuzioFederico Caligaris-Cappio
Dec 15, 2015·Expert Review of Clinical Immunology·Laleh SharifiAsghar Aghamohammadi
Jan 25, 2011·Expert Opinion on Investigational Drugs·Udo HoltickMartin R Weihrauch
Nov 14, 2015·British Journal of Haematology·Tina BagratuniEfstathios Kastritis
Sep 21, 2013·Critical Reviews in Oncology/hematology·Sara HarsiniNima Rezaei
Aug 13, 2014·Journal of Hematology & Oncology·Johana M Isaza-CorreaLydia Visser
Dec 26, 2012·Blood Cells, Molecules & Diseases·Predrag RodicDragana Janic
Feb 22, 2012·Blood Cells, Molecules & Diseases·David ChironCatherine Pellat-Deceunynck
Jan 18, 2011·Critical Reviews in Oncology/hematology·Jahangir AbdiFrank Redegeld
Sep 11, 2010·The Journal of Surgical Research·Linda J Adepoju, James D Geiger
Jul 3, 2010·Leukemia Research·David ChironCatherine Pellat-Deuceunynck
Mar 4, 2009·Current Problems in Cancer·S Vincent Rajkumar
May 23, 2014·Immunologic Research·Claire M Buchta, Gail A Bishop
Jan 14, 2010·Immunology·Isabelle Bekeredjian-Ding, Gaetan Jego
Nov 24, 2007·European Journal of Immunology·Bruno SalaunSerge Lebecque
Aug 10, 2007·British Journal of Haematology·Guy PrattPaul Moss
Jun 11, 2008·Immunology·Wendy W C van MarenGosse J Adema
Oct 21, 2010·Annals of the New York Academy of Sciences·Clara LocherLaurence Zitvogel
Oct 12, 2013·European Journal of Haematology·Nishant TagejaOla Landgren
Dec 20, 2008·Cellular & Molecular Biology Letters·Anna WolskaTadeusz Robak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.